MYLK3 and ovarian cancer: ALG5 expression is not associated with known prognostic biomarkers for ovarian cancer including molecular subtypes, MYLK3 promoter methylation or CT-based biomarker RPV, suggesting ALG5 may represent a novel biological pathway not affected by CGR.